Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China6 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration | Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD | Recruiting | Phase 2 | 2026-08-20 | NCT07776522 | |
| Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Site, Thoracic Neoplasms, endocrine system disorder, liver disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic ductal adenocarcinoma, pancreatic neoplasm, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Phase 2 | 2026-08-04 | NCT07745790 | |
| A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma | Moderate to Severe Asthma | Recruiting | Phase 3 | 2026-04-28 | NCT07372287 | |
| Phase II Clinical Trial of KJ101in the Treatment of Deep II Degree Burns | burn, injury | Recruiting | Phase 2 | 2025-06-17 | NCT07025408 | |
| The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Not stated | 2024-10-02 | NCT06623487 | |
| A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma | Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, neoplasm, osteosarcoma, sarcoma | Not yet recruiting | Phase 1 / Phase 2 | 2022-10-21 | NCT05590572 |